In a sector note on U.S. Medical Supplies and Devices, UBS initiated coverage of Insulet with a Neutral rating and $328 price target. Despite a strong growth trajectory, with Insulet shares trading a full turn above its 5-year historical averages and well above the ~9x EV/sales average multiple for the comparable SMID-Cap group from a sales growth perspective, the bullish Omnipod 5 outlook seems largely priced in, the analyst tells investors in a research note. UBS believes there is risk of multiple contraction to more in line with historical levels as growth decelerates in 2024 and beyond.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on PODD:
- Insulet initiated with a Neutral at UBS
- Insulet to replace SVB Financial in S&P 500 at open on 3/15
- Insulet price target raised to $334 from $320 at Raymond James
- Insulet price target raised to $350 from $340 at Baird
- Insulet price target raised to $292 from $245 at Barclays
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue